Cirio advised Alvotech on a private placement of SEK 750 million

Cirio has advised Alvotech in connection with a private placement of Swedish depositary receipts (“SDRs”) and ordinary shares raising gross proceeds of SEK 750 million to the company.

The price was determined through an accelerated bookbuilding process and the SDRs and ordinary shares were acquired by Swedish and international institutional investors. The SDRs and ordinary shares in the private placement will be made available through existing treasury shares held by Alvotech.

Alvotech is a global biotech company specializing in the development and production of biosimilars for patients worldwide. Alvotech’s shares are listed on Nasdaq Iceland Main Market in Iceland, Nasdaq Global Market in the United States and, in the form of SDRs, Nasdaq Stockholm.

Cirio advised Alvotech with a team headed by Maria Arnoldsson, together with Martin Näslund, Selma Didriksson Fröjd (Equity Capital Markets and Public M&A) and Carl-Axel Morvay (Banking & Finance and DCM).

For more information, please contact: